Dermatological Drugs Market Forecast 2015-2025: Opportunities for Leading Companies
NEW YORK, July 6, 2015 /PRNewswire/ -- Report Details
Dermatological drugs - new study showing you trends, partnerships, and predicted revenues
Where is the market for dermatological drugs heading? What are the commercial prospects for this market? Visiongain's new report shows you potential revenues and other trends to 2025, discussing data, opportunities and prospects.
Our 310 page report provides 220 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at world market, submarket, regional and national level. You will see financial results, interviews, trends, opportunities and revenue predictions.
Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter's Five Forces), company profiles and commercial developments. Read the full transcript of an exclusive expert opinion interview from an industry specialist informing your understanding and allowing you to assess prospects for investments and sales:
- Kathleen Deardorff, Chief Operating Officer (COO) at Photocure ASA
You will find prospects for key submarkets
In addition to analyses of the overall world market, you will see revenue forecasting of five world-level submarkets to 2025:
- Skin infection drugs market forecast 2015-2025
- Dermatitis drugs market forecast 2015-2025
- Acne drugs market forecast 2015-2025
- Psoriasis drugs market forecast 2015-2025
- Other dermatological drugs market forecast 2015-2025
See revenue forecasts for products
How will leading drugs perform to 2025 at world level? Our study forecasts sales of 24 products, including these brands:
- Remicade
- Humira
- Claravis
- Epiduo
- Bepanthen
- Solodyn
- Enbrel
- Protopic
- Cubicin
- Canesten
Discover how high revenues can go. You will see what's happening, understanding trends, challenges and opportunities.
What are the prospects for the leading regions and countries?
Our analyses show sustained growth in the dermatological drugs market, particularly in the emerging economies where growing affluence and rising government support will impact the growth of dermatological drugs.
In addition to analyses of the overall world market, you discover individual revenue forecasts for national and regional markets to 2025. Future trends within each region are examined. You will discover individual revenue forecasts for 12 leading national markets to 2025. There are many commercial opportunities to exploit in both developed and developing countries.
- US
- China
- Japan
- Germany
- India
- France
- UK
- Italy
- Spain
- Brazil
- Russia
- Mexico
- Rest of the World
Our analyses show that emerging economies, particularly in South America and Asia, will continue to achieve high revenue growth to 2025. Various economic, geographical, and regulatory factors globally will influence the market.
Leading companies and potential for market growth
Over the last few years, the market for dermatological drugs globally has witnessed a number of strategic acquisitions and restructuring. The global dermatological drugs market will reach $24.5bn in 2015, according to visiongain's forecast. Rising demand for dermatological drugs, expanding healthcare coverage, the success of biological drugs, and antibacterial drug resistance will aid in the growth of the overall market to 2025.
Our work shows you what organisations hold greatest potential. See profiles of 6 leading companies, including these:
- AbbVie
- Galderma
- GlaxoSmithKline
- Johnson & Johnson
- LEO Pharma
- Pfizer
A company profile gives you the following information:
- Revenue forecast for dermatological drugs from 2015 to 2025
- Recent financial results
- Assessment of recent developments - mergers and acquisitions (M&A), and collaborations, including alliances, partnerships, and joint ventures
- Discussion of a company's activities and outlook
Discover capabilities, progress, and commercial prospects, helping you stay ahead. What effects will regulatory changes have?
Research and development activities – assess innovation, trends and possibilities
What is happening in the R&D pipeline for dermatological treatments? You see developmental trends, gaining insight into each phase of the dermatology R&D pipeline for:
- Acne pipeline drugs
- Dermatitis pipeline drugs
- Psoriasis pipeline drugs
- Skin infections pipeline drugs
- Other progress in dermatology
Our study also discusses these agents and technologies, among others:
- Photodynamic therapy
- Drug delivery
- Novel small molecules
- Oral drug candidates
What issues will affect the dermatological drugs market?
Our new report lets you assess industry trends and outlooks. Our study discusses issues affecting dermatological treatments. You will find discussions, including qualitative analyses:
- Pricing and reimbursement pressures created by government cost-cutting initiatives
- Patient compliance and the advances in topical drug delivery
- A strong R&D pipeline
- Personalised dermatology and genomics
- Consolidation among players in the market
- Patent expiries and generic competition
- The changing socio-economic conditions impacting dermatological drug demand
- Demographic trends impacting demand for dermatological drugs
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape
How the Dermatological Drugs Market Forecast 2015-2025: Opportunities for Leading Companies report helps you
In summary our 310 page report gives you the following knowledge:
- Revenues to 2025 for the overall dermatological drugs market – discover the industry's prospects, finding promising areas for investments and revenues
- Revenue forecasts to 2025 for four product categories (therapeutic classes) within dermatological drugs – discover forecasts for Psoriasis drugs, Dermatitis drugs, Acne drugs, Skin infection drugs, and Other dermatological drugs
- Revenue forecast to 2025 for 12 leading national markets - US, China, Japan, India, Germany, France, UK, Italy, Spain, Russia, Brazil, Mexico, and Rest of the World
- Assess leading companies – hear about the products, results and strategies, including recent activities, future outlook, and dermatological drugs revenue forecast for 6 leading companies, including Pfizer, LEO Pharma, Johnson & Johnson, AbbVie, and GlaxoSmithKline
- Discussion of what stimulates and restrains companies and the market
- Prospects for established firms and those seeking to enter the market
- Opinions from our survey, seeing interviews with industry authorities
- IP protection and generic drug competition - see what affects product revenue
You will find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain's study is for everybody needing commercial analyses for the dermatological drugs market and the leading companies within it. You will find data, trends and predictions. Please order our report now.
Read the full report: http://www.reportlinker.com/p03083800-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article